New Mental Health Counseling Center Now Opens in Tampa Bay, FL - Online Free Press release news distribution topwirenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from topwirenews.com Daily Mail and Mail on Sunday newspapers.
Investment breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns
Media
Links
Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M
One of the most successful inventors and entrepreneurs who masterminded the unprecedented success of Qiagen N.V. from a start-up to a 10 billion market cap enterprise has taken the decision to refocus his activities on BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB). BrainRepair UG has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year. Metin Colpan’s patented invention has become a standard method recommended by the World Health Organization (WHO) and is used by researchers all over the world, changing the way they can access, purify and understand genetic data in DNA and RNA. The European Patent Office states “ The tireless work of Ge
UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Search jobs 25-May-2021 UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York
My Personal Therapeutics Ltd. (trading as
My Personal Therapeutics announced an exclusive license of the Personal Discovery Process technology from Mount Sinai for global commercialization. PDP leverages Big Data to build personalized fruit fly avatars that model the genetic complexity of each patient s unique tumor network. Using advanced robotics, thousands of FDA approved drugs are screened in a variety of combinations to identify drug cocktails designed to target tumors. Today, the company announces the expansion of licensed processes to include exclusive drug discovery and development rights.